Jeanne Marie Schilder - Indiana University School of Medicine

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 89 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Niraparib As First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study

Dana M. Chase,Maya Hanna, Jonathan T. Lim,Tirza Areli Calderón Boyle, Mark Guinter, Madeline Richey,Khilna Patel,Jeanne M. Schilder,Jean A. Hurteau,Amanda K. Golembesky

Oncology and Therapypp.1-10, (2025)

Cited0Views0WOSBibtex

Real-world Outcomes of First-Line Maintenance Niraparib Monotherapy in Patients with Epithelial Ovarian Cancer

Ritu Salani,Tirza Areli Calderon Boyle,Jonathan Lim,Jeanne M. Schilder,Jean A. Hurteau,Jessica Perhanidis,Amanda Golembesky,Floor J. Backes

FUTURE ONCOLOGY（2025）

Cited0Views0WOSBibtex

The BEV1L Study: Do Real-World Outcomes Associated with the Addition of Bevacizumab to First-Line Chemotherapy in Patients with Ovarian Cancer Reinforce Clinical Trial Findings

Linda R Duska, Jonathan Lim, Tirza Areli Calderón Boyle, Mark Guinter, Siobhan Halloran, John Hartman,Jeanne M Schilder,Jean A Hurteau, Amanda K Golembesky

Cancerno. 10 (2025): e35821-e35821

Cited0Views0WOSBibtex

PR032/#594 Real-world Monitoring of Platelet Counts among Patients with Epithelial Ovarian Cancer Receiving First-Line Maintenance Niraparib in the United States: the ACTIV1ZE Study

Fernanda Musa, Tirza Boyle,Jonathan Lim, Julia Moore,Jeanne Schilder,Jean Hurteau,Amanda Golembesky,Lisa Landrum

International Journal of Gynecological Cancer (2024): A56-A57

Cited0Views0Bibtex

The BEV1L Study: Do Real-World Outcomes Associated with the Addition of Bevacizumab to First-Line Chemotherapy in Patients with Ovarian Cancer Reinforce Clinical Trial Findings

Linda R. Duska,Jonathan Lim,Tirza Areli Calderon Boyle, Mark Guinter, Siobhan Halloran,John Hartman,Jeanne M. Schilder,Jean A. Hurteau,Amanda Golembesky

Journal of Clinical Oncology（2024）

Cited0Views0Bibtex

The Potential Impact of Excluding Patients with Stage III Epithelial Ovarian Cancer and No Postoperative Visible Residual Disease from the PRIMA/ENGOT-OV26/GOG-3012 Trial: the AR1ZE Real-World Study of Niraparib First-Line Maintenance Therapy

Dana Chase,Maya Hanna,Jonathan Lim,Tirza Areli Calderon Boyle, Mark Guinter, Madeline Richey,Khilna Patel,Jeanne Schilder,Jean Hurteau,Amanda Golembesky

GYNECOLOGIC ONCOLOGY (2024): S215-S216

Cited0Views0Bibtex

Correlation Between Real-World Progression-Free Survival and Other Outcomes among Patients with Ovarian Cancer Who Received Poly(adp-Ribose) Polymerase Inhibitors in the First-Line Maintenance Setting

Monica Kobayashi,Soham Shukla,Cheryl Xiang,Samantha Valliant, Kejsi Begaj,Sophie Gao, Hesen Li,Jinlin Song,Jeanne Schilder

GYNECOLOGIC ONCOLOGY (2024): S213-S214

Cited1Views0Bibtex

Cervicovaginal Metabolome is Predictive of Endometrial Cancer and Tumor Characteristics and Leveraged for Risk Stratification

Dana Chase,Soham Shukla, Julia Moore, Tirza Boyle,Jonathan Lim,Jessica Perhanidis,Jean Hurteau,Jeanne Schilderd

GYNECOLOGIC ONCOLOGY (2024): S398-S399

Cited0Views0Bibtex

Characteristics and Real-World Outcomes of Patients with Epithelial Ovarian Cancer Who Received Niraparib Plus Bevacizumab First-Line Maintenance Therapy in the COMB1NE Study

Premal H. Thaker,Tirza Boyle,Jessica Perhanidis, Sara Burns,Jonathan Lim,John Hartman,Linda Kalilani,Jeanne Schilder,Jean Hurteau,Amanda Golembesky

GYNECOLOGIC ONCOLOGY (2024): S199-S200

Cited0Views0WOSBibtex

Ovarian Cancer Retrospective European (o'care) Study: First-Line Outcomes by Number of Risk Factors for Progression

Jonathan Krell,Danielle Shaw,John McGrane,Andreas Hartkopf,Ana Herrero, Cheng Yeoh,Maria Masvidal,Francesco Raspagliesi,Whitney York,Jeanne M. Schilder, Barbara Mascialino,Eleanor McDermott,Linda Kalilani,Lars Hanker

FUTURE ONCOLOGY（2024）

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn